Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer

Mei Zhao,1,2 Lijuan Fu,1,2 Panling Xu,1,2 Ting Wang,1,2 Ping Li1,2 1Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 2Department of Integrated Traditional Chinese and Western Medicine, Anhui Medical Uni...

Full description

Bibliographic Details
Published in:	Drug Design, Development and Therapy
Main Authors:	Zhao M, Fu L, Xu P, Wang T, Li P
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-03-01
Subjects:	kanglaite injection triple-negative breast cancer network pharmacology cell cycle cdk1
Online Access:	https://www.dovepress.com/network-pharmacology-and-experimental-validation-to-explore-the-effect-peer-reviewed-fulltext-article-DDDT

Similar Items

Critical Response to Article “Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer” [Letter]
by: Dany F, et al.
Published: (2023-08-01)

Kanglaite (Coix Seed Extract) as Adjunctive Therapy in Cancer: Evidence Mapping Overview Based on Systematic Reviews With Meta-Analyses
by: Cuncun Lu, et al.
Published: (2022-08-01)

Pharmacological mechanisms of berberine against triple negative breast cancer: Integration of network pharmacology and experimental validation
by: Tian Qin, et al.
Published: (2025-08-01)

Network pharmacological analysis and in vitro testing of the rutin effects on triple-negative breast cancer
by: Chang Cheng, et al.
Published: (2025-01-01)

Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
by: Ruike Gao, et al.
Published: (2021-03-01)

Role of flavonoids in inhibiting triple-negative breast cancer
by: Shuai Wang, et al.
Published: (2024-08-01)

CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer
by: Jianming Tang, et al.
Published: (2024-07-01)

Network Pharmacology, Molecular Docking, and Molecular Dynamics Analysis of Honokiol against Triple-negative Breast Cancer
by: Hassan H. Alhassan
Published: (2024-12-01)

Exploration of the Pharmacological Mechanism of Vitexicarpin against Triple-Negative Breast Cancer in Network Pharmacology
by: Tianhui Wu, et al.
Published: (2023-12-01)

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer
by: Paige Baldwin, et al.
Published: (2024-03-01)

Exploring the therapeutic potential and in vitro validation of baicalin for the treatment of triple-negative breast cancer
by: Yuan Ma, et al.
Published: (2025-04-01)

Unveiling the Mechanisms and Therapeutic Effects of Xiaoyao Sanjie Decoction in Triple-Negative Breast Cancer: A Network Pharmacology and Experimental Validation Approach
by: Qi Y, et al.
Published: (2024-12-01)

Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: Targeting EGFR and CDK4/6 pathways
by: Adyasa Samantaray, et al.
Published: (2025-06-01)

Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis
by: Zhitao Han, et al.
Published: (2023-09-01)

Integrating network pharmacology, molecular docking and experimental verification to explore the therapeutic effect and potential mechanism of nomilin against triple-negative breast cancer
by: Zhixuan Wu, et al.
Published: (2024-09-01)

Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
by: Magdalena Niedolistek, et al.
Published: (2020-04-01)

Does triple negative breast cancer subtype carry poorer prognosis as compared to non-triple negative breast cancer lesion - A study from a tertiary hospital
by: Srijan Basu, et al.
Published: (2023-11-01)

Novel CDK4/6 lnhibitor, WXJ-8 -Exerts Anti-effects Through Cell Cycle in Breast Cancer
by: Jing Ji, et al.
Published: (2023-11-01)

Induced Cell Cycle Arrest in Triple-Negative Breast Cancer by Combined Treatment of Itraconazole and Rapamycin
by: Hua-Tao Wu, et al.
Published: (2022-04-01)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
by: Jiahao Qiu, et al.
Published: (2022-04-01)

Platinum chemotherapy for early triple-negative breast cancer
by: Sofia RE. Mason, et al.
Published: (2024-06-01)

High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer
by: Xinkui Liu, et al.
Published: (2021-09-01)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
by: Yajing Huang, et al.
Published: (2020-10-01)

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
by: Cun Liu, et al.
Published: (2019-10-01)

Immunotherapy Treatment for Triple Negative Breast Cancer
by: Elizabeth R. Berger, et al.
Published: (2021-08-01)

Triple-negative breast cancer: Pattern of recurrence and survival outcomes
by: Shyny Reddy Chintalapani, et al.
Published: (2019-01-01)

Immunotherapy in Triple-Negative Breast Cancer
by: Elisa Tiberi, et al.
Published: (2025-05-01)

c-MYC Levels and Metabolic Parameters in Triple-Positive and Triple-Negative Breast Cancer
by: Doaa N. Abood, et al.
Published: (2025-06-01)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
by: Jingyu Peng, et al.
Published: (2021-05-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

Mechanisms of Yiai Fuzheng formula in the treatment of triple-negative breast cancer based on UPLC-Q-Orbitrap-HRMS, network pharmacology, and experimental validation
by: Ruijie Li, et al.
Published: (2024-09-01)

Response to cisplatin in a metastatic triple-negative breast cancer patient
by: Budhi Singh Yadav, et al.
Published: (2021-01-01)

Profile and Outcome of Triple Negative Breast Cancer at a Tertiary Care University Hospital in Nepal
by: Suman Khanal, et al.
Published: (2020-06-01)

C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple‐negative breast cancer
by: Li Liao, et al.
Published: (2023-11-01)

The Immunomodulatory Role of Gemcitabine in Triple Negative Breast Cancer
by: Cory Fines, et al.
Published: (2025-10-01)

Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative Breast Cancer
by: Fan T, et al.
Published: (2024-04-01)

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
by: Bradley A. Hancock, et al.
Published: (2019-08-01)

Blestriarene C exerts an inhibitory effect on triple-negative breast cancer through multiple signaling pathways
by: Junsha An, et al.
Published: (2024-10-01)

Potential target and mechanism exploration from α-mangostin against triple-negative breast cancer: An in silico study
by: Rafly Mochamad Rivaldo, et al.
Published: (2024-07-01)

Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients
by: Shi H, et al.
Published: (2019-12-01)